U.S. Markets open in 1 hr 49 mins

Edited Transcript of ZYNE earnings conference call or presentation 2-Aug-18 12:30pm GMT

Q2 2018 Zynerba Pharmaceuticals Inc Earnings Call

DEVON Aug 14, 2018 (Thomson StreetEvents) -- Edited Transcript of Zynerba Pharmaceuticals Inc earnings conference call or presentation Thursday, August 2, 2018 at 12:30:00pm GMT

TEXT version of Transcript

================================================================================

Corporate Participants

================================================================================

* Armando Anido

Zynerba Pharmaceuticals, Inc. - Chairman & CEO

* James E. Fickenscher

Zynerba Pharmaceuticals, Inc. - CFO & VP of Corporate Development

* William C. Roberts

Zynerba Pharmaceuticals, Inc. - VP of IR & Corporate Communications

================================================================================

Presentation

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

Good morning, and welcome to the Zynerba Pharmaceuticals Second Quarter 2018 Business Update Conference Call. (Operator Instructions) As a reminder, today's conference call is being recorded.

I would now like to turn the call over to Will Roberts, Vice President, Investor Relations and Corporate Communications.

--------------------------------------------------------------------------------

William C. Roberts, Zynerba Pharmaceuticals, Inc. - VP of IR & Corporate Communications [2]

--------------------------------------------------------------------------------

Thank you, Tiffany. Good morning, everyone, and thank you for joining us on the call this morning. We issued a press release this morning announcing our second quarter 2018 financial results and providing a company update. This press release can be found on our website under the News section.

Before we begin, I'd like to remind you that today's webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect Zynerba's current expectations regarding future events, including, but not limited to, statements regarding design, initiation, timing, continuation and/or progress of the company's clinical trials and the company's ability to obtain and maintain regulatory approval for its product candidates and/or the label claims that it's seeking from FDA.

Additional results may differ materially from those expressed and/or implied by these statements as a result of various factors, including those discussed from time to time in the company's filings with the Securities and Exchange Commission on Form 10-K and in our periodic filings on Form 10-Q and 8-K and other filings made with the SEC. Links to these documents are available in the Investor Relations section of our website, and we encourage you to review these materials. Any forward-looking statements represent our views as of today, August 2, 2018.

With me on the call this morning is Armando Anido, our Chairman and Chief Executive Officer; Terri Sebree, our President; and Jim Fickenscher, our Chief Financial Officer and Vice President of Corporate Development.

I'll now turn the call over to Armando Anido. Armando?

--------------------------------------------------------------------------------

Armando Anido, Zynerba Pharmaceuticals, Inc. - Chairman & CEO [3]

--------------------------------------------------------------------------------

Thanks, Will, and good morning to everyone joining us on this call. It has been a busy and exciting few months for Zynerba. We initiated CONNECT-FX, a pivotal study in Fragile X. We presented compelling new data from the ongoing FAB-C study in Fragile X patients.

We initiated BELIEVE-1, a Phase II study in developmental and epileptic encephalopathies. We presented new long-term data from STAR 2 showing the benefits of ZYN002 in adults with refractory seizures.

We closed the $30 million follow-on offering on July 24 as expected that, we believe, extends our cash runway into the first half of 2020 and through it, gained new institutional shareholders.

And today, we announced our quarterly results for second quarter 2018. It's an exciting time. And as such, we want to use this call to provide a status update on the company and to discuss our upcoming milestones.

We are focused on rare and near-rare neuropsych disorders with the pipeline targeting conditions, including Fragile X syndrome, DEE such as Dravet and Lennox-Gastaut and adult refractory focal seizures.

Our lead program is ZYN002 in Fragile X, a disease caused by a genetic mutation in the FMR1 gene that dysregulates the endocannabinoid system in the central nervous system. This dysregulation is central to clinical abnormalities seen in Fragile X patients. CBD may attenuate the loss of endogenous endocannabinoid signaling in Fragile X and improve behavioral symptoms.

As we announced in early July, we initiated CONNECT-FX, a pivotal study in Fragile X children. This multinational, double-blind, placebo-controlled 14-week study is currently enrolling patients from 3 to 17 years old who have a full mutation of the FMR1 gene. We are targeting 204 patients with a one-to-one randomization of active drug to placebo in approximately 20 sites in the U.S., Australia and New Zealand. The primary endpoint of this trial is the change in social avoidance behavior evaluated using the Aberrant Behavior Checklist, or ABC, for Fragile X. Key secondary endpoints include the ABC irritability and social withdrawal/lethargic subscales and clinicians' global impression improvement anchored to behavioral symptoms of Fragile X. This study is powered at 90% to detect a treatment effect of 20% in the ABC social avoidance score between ZYN002 and placebo at a p-value of 0.05 or less.

We also presented new data from the open-label FAB-C trial at the July International Fragile X Conference, demonstrating that after 12 weeks of treatment with ZYN002, patients achieved a statistically significant mean improvement of 58% versus baseline in social avoidance as measured by the ABC social avoidance subscale. This is the same subscale we are utilizing as our primary endpoint in CONNECT-FX. And after 38 weeks of treatment with ZYN002, patients achieved a statistically significant mean improvement of 75% versus baseline in that same subscale.

ZYN002 was well tolerated with an adverse event profile similar to that previously reported, and no clinically meaningful trends in vital signs or clinical laboratory evaluations were observed.

Based on these compelling data, we are confident with the primary endpoint and trial design for CONNECT-FX. The CONNECT-FX top line trial results are expected in the second half of 2019. And assuming positive results, we will quickly request a meeting with the FDA to discuss the path to NDA submission. We believe that CONNECT-FX will be the only trial required by the FDA, assuming positive results.

Next is our program in DEE, a group of rare and ultra-rare epilepsy syndromes that involve significant developmental impairment or regression of developmental progress, including Doose, Dravet, early myoclonic encephalopathy, Lennox-Gastaut and West syndromes, among a number of others. They are often progressive and highly resistant to current treatment options, an unmet medical need we hope to address with ZYN002.

In April, we initiated BELIEVE-1, a 6-month open-label Phase II clinical trial evaluating the efficacy and safety of ZYN002 in approximately 50 children and adolescents with various DEEs. We are actively enrolling patients in Australia and New Zealand. The primary efficacy assessment is the change in seizure frequency versus baseline. We are thrilled with the rate of enrollment in this trial. We expect to present top line data in 2019. And when the trial is fully enrolled, we will provide more specificity on when in 2019 we will release this data.

Later this half, we expect to initiate our double-blind, placebo-controlled Phase IIb trial of ZYN002 in adult refractory focal seizures, which is the most common form of epilepsy. Over 1/3 of the 1.5 million focal seizure patients suffer uncontrolled seizures despite being on multiple antiepileptic drugs. Our trial is expected to enroll approximately 300 adult focal epilepsy patients from sites in the U.S., Australia and New Zealand. The primary endpoint will be reduction from baseline in focal seizures. The compelling results of our STAR 2 extension study, including continued reductions in seizures through 12 months of treatment with ZYN002, have contributed to the design of this study. The new trial design will include an increase in baseline seizure frequency, stratification by gender and an increase in the duration of the study. More to come as we initiate this trial later this half.

Just as our pipeline has evolved so has our capitalization. Thanks to our recent financing, which closed, as expected, on July 24 and added $30 million net to our cash position. The 30-day underwriters' option to purchase additional shares is still open and expires on August 19. We estimate that our current cash position, including the proceeds of the offering, provides funding to get us past top line data readouts from CONNECT-FX and BELIEVE-1 and, if the CONNECT-FX data are positive and the regulatory interactions supportive, fund the filing of our NDA for ZYN002 in Fragile X. Clearly, this is a very exciting time at Zynerba.

I will now turn this call over to Jim Fickenscher for a quick review of the financial results. Jim?

--------------------------------------------------------------------------------

James E. Fickenscher, Zynerba Pharmaceuticals, Inc. - CFO & VP of Corporate Development [4]

--------------------------------------------------------------------------------

Thanks, Armando, and good morning, everyone. For the 3 months ended June 30, 2018, we incurred a net loss of $12 million or $0.89 per share compared to a net loss for the same period of 2017 of $8.3 million or $0.64 per share. Included in the net loss amounts are $1.8 million and $1.4 million of noncash stock-based compensation expense, respectively.

Research and development expenses increased by $2.8 million to $8.5 million for the second quarter of 2018. The increase was primarily related to higher manufacturing and clinical trial costs related to our product candidates and higher personnel costs, including stock-based compensation expense.

General and administrative expenses increased by $0.8 million to $3.4 million in the second quarter of '18. The increase was primarily related to increases in expenses associated with personnel costs, including stock-based compensation expense and an increase in free commercialization expense for our product candidates.

As of June 30, our cash and cash equivalents are $43.1 million, down $9 million from the March 31 balance. Please note that the $30 million in proceeds from the July 2018 secondary offering are not included in the $43-point million (sic) [$43.1 million], as this will be recorded in the third quarter financial statements.

Thank you for your attention this morning. I'll now turn the call back over to Armando for some concluding remarks.

--------------------------------------------------------------------------------

Armando Anido, Zynerba Pharmaceuticals, Inc. - Chairman & CEO [5]

--------------------------------------------------------------------------------

Thanks, Jim. Zynerba's purpose has always been to deliver novel medications to patients who need them the most, those who are refractory to current therapeutic options and those suffering from diseases that today have no approved therapeutic alternatives. Thanks to our achievements and momentum, we continue to move ever closer to potentially realizing that purpose and are well capitalized to continue to execute on our business plans.

Throughout this year and next, our pipeline will continue to evolve. We have 6 key clinical goals that we expect to achieve over the next 18 months: first, complete CONNECT-FX and report top line results in the second half of 2019; second, complete BELIEVE-1 in DEE and report top line results in 2019; third, initiate the adult refractory focal seizure trial later this half; fourth, present longer-term data from the FAB-C study and Fragile X by year-end; fifth, present longer-term data from STAR 2 in adults with refractory focal seizures later this year; and finally, with clinical and regulatory success in Fragile X, file our first NDA. And very importantly, we believe we have the capital to achieve all of these goals. As we approach and achieve these milestones, I believe we are well positioned to generate excellent returns to all of our shareholders.

With that, I'll open the call up to Q&A. Operator, can you please give the instructions on how to initiate a question.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions)

--------------------------------------------------------------------------------

Armando Anido, Zynerba Pharmaceuticals, Inc. - Chairman & CEO [2]

--------------------------------------------------------------------------------

Oh, it appears things are a little quiet this morning. So I want to take this time to thank everybody for participating on the call and happy to follow up with any individual investors who would like to talk personally. Thank you all. Have a great day.

--------------------------------------------------------------------------------

Operator [3]

--------------------------------------------------------------------------------

Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program. You may now disconnect. Everyone, have a great day.